Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : IMR-687
CAS No.: 2062661-53-2
Catalog No.: PC-72172Not For Human Use, Lab Use Only.
IMR-687 (IMR687, Tovinontrine) is a novel, potent and selective phosphodiesterase-9 (PDE-9) inhibitor with IC50 of 8.19 nM and 9.99 nM against PDE9A1 and PDE9A2, respectively.
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 5 mg | $258 | In stock | |
| 10 mg | $398 | In stock | |
| 25 mg | $598 | In stock | |
| 50 mg | Get quote | ||
| 100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
IMR-687 (IMR687, Tovinontrine) is a novel, potent and selective phosphodiesterase-9 (PDE-9) inhibitor with IC50 of 8.19 nM and 9.99 nM against PDE9A1 and PDE9A2, respectively.
IMR-687 (Tovinontrine) displays>800-fold greater potency than PDE1A3, PDE1B, PDE1C, PDE5A2 (IC50 values >8 uM).
IMR-687 (Tovinontrine) recapitulates the cGMP and fetal hemoglobin (HbF) induction mechanism of hydroxyurea (HU) in erythroid cells.
Treatment of phosphodiesterase 9A inhibitor (IMR-687, Tovinontrine) in sickle mice for 30 days results in fetal hemoglobin (HbF) induction, reduced hemolysis and reticulocytosis, as well as immune cell activity.
IMR-687 (Tovinontrine) increases F-cells in patient-derived sickle cell disease (SCD) CD36+ cells, reduces vessel-occlusion in the Townes-HbSS sickle cell disease model.
| M.Wt | 394.479 | |
| Formula | C21H26N6O2 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
| Chemical Name/SMILES |
6-{(3S,4S)-4-methyl-1-[(pyrimidin-2-yl)methyl]pyrrolidin-3-yl}-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8(7H)-one |
|
1. McArthur JG, et al. Haematologica. 2020 Mar;105(3):623-631.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
